• search hit 4 of 6
Back to Result List

A review of the pharmaceutical R&D efficiency : costs, timelines, and probabilities

  • It is known that the costs related with drug research and development (R&D) and the timelines to develop a new drug increased over the past years. In parallel, the success rates of drug projects along the pharmaceutical R&D phases are still very low, and the outcome of all R&D efforts is stagnating. In consequence, the R&D efficiency defined as the financial investment per drug has been steadily decreasing. As innovation is the major growth driver of the pharmaceutical industry, reliable data on R&D efficiency and new concepts to overcome these challenges are of great interest for R&D managers and the sustainability of the pharmaceutical industry as a whole. This book chapter reviews publications on R&D performance indicators of the past years, such as the success rates and timelines per phase. Additionally, it illustrates the factors influencing the success rates, timelines, and costs of pharmaceutical R&D most and, thus, the denominators of the R&D efficiency.

Download full text files

  • 661.pdf
    eng

Export metadata

Additional Services

Share in Twitter Search Google Scholar
Metadaten
Name:Schuhmacher, Alexander
DOI:https://doi.org/10.1002/9783527693405.ch4
ISBN:978-3-527-69340-5
Erschienen in:Value creation in the pharmaceutical industry : the critical path to innovation
Publisher:Wiley-VCH
Place of publication:Weinheim
Editor:Alexander Schuhmacher
Document Type:Part of a Book
Language:English
Year of Publication:2016
Tag:R&D efficiency; R&D timelines; costs of drug development; success rates of pharmaceutical R&D
Pagenumber:19
First Page:61
Last Page:79
Catalogue entry:Im Katalog der Hochschule Reutlingen ansehen
Dewey Decimal Classification:330 Wirtschaft
540 Chemie
Open Access:Nein
Licence (German):License Logo  Lizenzbedingungen Wiley